Inogen Inc
$ 5.84
2.82%
24 Feb - close price
- Market Cap 154,203,000 USD
- Current Price $ 5.84
- High / Low $ 5.95 / 5.64
- Stock P/E N/A
- Book Value 7.26
- EPS -1.00
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.13 %
- 52 Week High 11.94
- 52 Week Low 5.48
About
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.
Analyst Target Price
$13.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-07 | 2023-05-04 | 2023-02-23 |
| Reported EPS | -0.2 | -0.15 | -0.11 | -0.24 | -0.25 | -0.24 | -0.62 | -1.14 | -0.55 | -0.42 | -0.88 | -0.2 |
| Estimated EPS | -0.21 | -0.27 | -0.25 | -0.49 | -0.49 | -0.55 | -0.76 | -0.62 | -0.49 | -0.59 | -0.81 | -0.57 |
| Surprise | 0.01 | 0.12 | 0.14 | 0.25 | 0.24 | 0.31 | 0.14 | -0.52 | -0.06 | 0.17 | -0.07 | 0.37 |
| Surprise Percentage | 4.7619% | 44.4444% | 56% | 51.0204% | 48.9796% | 56.3636% | 18.4211% | -83.871% | -12.2449% | 28.8136% | -8.642% | 64.9123% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INGN
2026-02-23 19:34:01
Inogen Inc. has introduced its new Aurora CPAP mask line in the U.S., marking its entry into the sleep apnea market and expanding its respiratory care portfolio. The line includes full face, nasal cushion, and nasal pillows options, all designed for comfort, compatibility, and ease of use. This launch follows FDA clearance and a patient-use study showing high satisfaction.
2026-02-20 22:25:22
Inogen Inc (INGN) is projected to report a loss of 36 cents per share, according to a recent earnings preview. This forecast is based on information from Refinitiv. The article provides a brief earnings outlook for the company.
2026-02-18 13:57:07
Inogen (INGN) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended December 2025, with results due on February 24. Despite a consensus outlook predicting a quarterly loss of $0.36 per share, slightly better than the previous year, the estimate has been revised 5.26% lower recently. With an Earnings ESP of 0% and a Zacks Rank #2, it's difficult to conclusively predict whether Inogen will beat or miss the consensus EPS estimate.
2026-02-17 15:57:58
Inogen (INGN) is expected to report a quarterly loss of $0.36 per share, an improvement from the previous year, with revenues projected to increase by 2.4% to $82 million for the quarter ended December 2025. Despite a Zacks Rank #2 (Buy), the company has an Earnings ESP of 0%, making it difficult to confidently predict an earnings beat. Investors are advised to consider other factors alongside the Earnings ESP and Zacks Rank when evaluating the stock.
2026-02-17 11:24:46
Inogen (NASDAQ:INGN) is set to release its Q4 2025 earnings after the market closes on Tuesday, February 24, 2026. Analysts project an EPS loss of ($0.36) and revenue of $82.0 million for the quarter. The medical technology company, with a market capitalization of $156.38 million, has seen institutional investors acquire significant stakes, while analyst ratings are mixed with an average "Hold" rating and a consensus target price of $11.00.
2026-02-11 21:22:00
Inogen (INGN) shares rose 6.6% after the company provided an encouraging preliminary revenue update for Q4 2025, showing modest top-line growth and expected positive adjusted EBITDA for the full year. While expected revenues are up 2.4% year over year, the consensus EPS estimate for the upcoming quarter has been revised 5.3% lower, suggesting potential headwinds despite the recent stock jump. Inogen currently holds a Zacks Rank #2 (Buy).
